直接抗病毒药物治疗儿童丙型肝炎的研究进展
Research Progress of Direct Antiviral Drug Therapy for Hepatitis C in Children
DOI: 10.12677/ACM.2023.131022, PDF,   
作者: 孔繁娇, 任晫煦, 郝 帅, 罗羽杉, 田亚文, 赵梓棋, 豆文丽：西安医学院，陕西 西安；贺 娜, 刘凯歌：西安医学院第一附属医院，陕西 西安
关键词: 丙肝；儿童；直接抗病毒药物；治疗；Hepatitis C； Children； Direct Antiviral Drug； Treatment
摘要: 随着直接抗病毒药物(DAAs)在成人丙型肝炎治疗的应用，慢性丙型肝炎的根治目标将在不久后实现。然而，在儿童HCV患者治疗方面，DAAs的应用仍存在很多不明确的地方。本篇综述主要总结分析了关于治疗儿童丙肝的直接抗病毒药物的最新研究进展，以供了解最新DAAs药物对儿童丙肝病毒治疗管理的现状，为我国制定符合本土儿童丙肝患者特点的用药方案提供可用的思路。
Abstract: With the application of direct antiviral drug therapy (DAAs) in the treatment of adult Hepatitis C, the goal of eradicating chronic hepatitis C will be achieved in the near future. However, there are still many uncertainties in the application of DAAs in the treatment of children with HCV. This re-view summarizes and analyzes the latest research progress on the direct antiviral drug of Hepatitis C treatment in children. It provides an insight into the current status of DAAs Drug Administration in the treatment of Hepatitis C virus in children, it provides a useful way of thinking for our country to formulate the medication scheme which accords with the characteristics of native children with Hepatitis C.
文章引用：孔繁娇, 贺娜, 任晫煦, 郝帅, 罗羽杉, 田亚文, 赵梓棋, 豆文丽, 刘凯歌. 直接抗病毒药物治疗儿童丙型肝炎的研究进展[J]. 临床医学进展, 2023, 13(1): 140-144. https://doi.org/10.12677/ACM.2023.131022

参考文献

[1] Messina, J.P., et al. (2015) Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology, 61, 77-87. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, Y.S., et al. (2011) A Sero-Epidemiological Study on Hepatitis C in China. Chinese Journal of Epidemiology, 32, 888-891.
[3] Marchesini, G., et al. (1999) Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. The American Journal of Medicine, 107, 450-455. [Google Scholar] [CrossRef] 
[4] Mohan, V., et al. (2009) Prevalence of Non-Alcoholic Fatty Liver Disease in Urban South Indians in Relation to Different Grades of Glucose Intolerance and Metabolic Syndrome. Diabetes Research and Clinical Practice, 84, 84-91. [Google Scholar] [CrossRef] [PubMed]
[5] Yeung, L.T., King, S.M. and Roberts, E.A. (2001) Moth-er-to-Infant Transmission of Hepatitis C Virus. Hepatology, 34, 223-229. [Google Scholar] [CrossRef] [PubMed]
[6] Ruiz-Extremera, A., et al. (2017) Influence of HLA Class I, HLA Class II and KIRs on Vertical Transmission and Chronicity of Hepatitis C Virus in Children. PLOS ONE, 12, e0172527. [Google Scholar] [CrossRef] [PubMed]
[7] Pawlowska, M., et al. (2015) What’s New in Hepatitis C Virus Infections in Children? World Journal of Gastroenterology, 21, 10783-10789. [Google Scholar] [CrossRef] [PubMed]
[8] Browning, J.D. and J.D. Horton, J.D. (2004) Molecular Mediators of Hepatic Steatosis and Liver Injury. The Journal of Clinical Investigation, 114, 147-152. [Google Scholar] [CrossRef] 
[9] Malhi, H. and Gores, G.J. (2008) Molecular Mechanisms of Lipotoxi-city in Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 28, 360-369. [Google Scholar] [CrossRef] [PubMed]
[10] Nydegger, A., et al. (2008) Health-Related Quality of Life in Children with Hepatitis C Acquired in the First Year of Life. Journal of Gastroenterology and Hepatology, 23, 226-230. [Google Scholar] [CrossRef] [PubMed]
[11] Pawlowska, M., Sobolewska-Pilarczyk, M. and Do-magalski, K. (2018) Hepatitis C Virus Infection in Children in the Era of Direct-Acting Antiviral. World Journal of Gas-troenterology, 24, 2555-2566. [Google Scholar] [CrossRef] [PubMed]
[12] Murray, K.F., et al. (2018) Safety and Efficacy of Ledipas-vir-Sofosbuvir with or without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology, 68, 2158-2166. [Google Scholar] [CrossRef] [PubMed]
[13] (2018) Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommenda-tions for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 67, 1477-1492. [Google Scholar] [CrossRef] [PubMed]
[14] Nwaohiri, A., et al. (2018) Hepatitis C Virus Infection in Children: How Do We Prevent It and How Do We Treat It? Expert Review of Anti-Infective Therapy, 16, 689-694. [Google Scholar] [CrossRef] [PubMed]
[15] 魏来, 段钟平, 王贵强. 丙型肝炎防治指南(2019年版) [J]. 实用肝脏病杂志, 2020, 23(1): 33-52.
[16] WHO (2016) Global Health Sector Strategy on Viral Hepatitis 2016-2021. World Health Organization, Geneva.
[17] Jara, P., et al. (2003) Chronic Hepatitis C Virus Infection in Childhood: Clinical Patterns and Evolution in 224 White Children. Clinical Infectious Diseases, 36, 275-280. [Google Scholar] [CrossRef] [PubMed]
[18] Hofmeister, M.G., et al. (2019) Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatology, 69, 1020-1031. [Google Scholar] [CrossRef] [PubMed]
[19] Sainz, T., et al. (2020) Longitudinal Evolution of Vertically HIV/HCV-Co-Infected vs HCV-Mono-Infected Children. Journal of Viral Hepatitis, 27, 61-67. [Google Scholar] [CrossRef] [PubMed]
[20] Indolfi, G., et al. (2019) Hepatitis C Virus Infection in Children and Ado-lescents. The Lancet Gastroenterology and Hepatology, 4, 477-487. [Google Scholar] [CrossRef] 
[21] Indolfi, G., et al. (2015) Histopathology of Hepatitis C in Children, a Systematic Review: Implications for Treatment. Expert Review of Anti-Infective Therapy, 13, 1225-1235. [Google Scholar] [CrossRef] [PubMed]
[22] Modin, L., et al. (2019) Epidemiology and Natural History of Hepatitis C Virus Infection among Children and Young People. Journal of Hepatology, 70, 371-378. [Google Scholar] [CrossRef] [PubMed]
[23] Mack, C.L., et al. (2012) NASPGHAN Practice Guidelines: Diag-nosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents. Journal of Pediatric Gastroenter-ology and Nutrition, 54, 838-855. [Google Scholar] [CrossRef] 
[24] 贺珊, 等. 直接抗病毒药物在儿童丙型病毒性肝炎感染中的应用[J]. 世界最新医学信息文摘, 2019, 19(78): 57-58+60.
[25] Balistreri, W.F., et al. (2017) The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12-17 Years Old with Hepatitis C Virus Genotype 1 Infection. Hepatology, 66, 371-378. [Google Scholar] [CrossRef] [PubMed]
[26] El-Khayat, H.R., et al. (2018) The Effectiveness and Safety of Ledipasvir plus Sofosbuvir in Adolescents with Chronic Hepatitis C Virus Genotype 4 Infection: A Re-al-World Experience. Alimentary Pharmacology & Therapeutics, 47, 838- 844. [Google Scholar] [CrossRef] [PubMed]
[27] Li, X., et al. (2018) Pharmacokinetics, Safety, and Tolerability of the Di-rect-Acting Hepatitis C Antiviral Sofosbuvir in Healthy Chinese Subjects. Clinical Therapeutics, 40, 1556-1566. [Google Scholar] [CrossRef] [PubMed]
[28] Wyles, D., et al. (2017) Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase II and III Clinical Trials of Ledipasvir/Sofosbuvir. Journal of Hepatology, 66, 703-710. [Google Scholar] [CrossRef] [PubMed]
[29] Gane, E.J., et al. (2017) Sofosbuvir-Velpatasvir with Ribavirin for 24 Weeks in Hepatitis C Virus Patients Previously Treated with a Direct-Acting Antiviral Regimen. Hepatology, 66, 1083-1089. [Google Scholar] [CrossRef] [PubMed]
[30] Statler, V.A. and Espinosa, C. (2020) Management of Hepatitis C in Children and Adolescents. Journal of the Pediatric Infectious Diseases Society, 9, 785-790. [Google Scholar] [CrossRef] [PubMed]
[31] Clemente, M.G., et al. (2020) Present and Future Management of Viral Hepatitis B and C in Children. Clinics and Research in Hepatology and Gastroenterology, 44, 801-809. [Google Scholar] [CrossRef] [PubMed]

为你推荐